SUMMARY A method for washing platelets by albumin density gradient separation has been modified to prepare platelet rich plasma of thrombocytopenic patients for platelet aggregation studies. The concentration procedure, consisting of centrifuging platelets into a specific gravity gradient between plasma and 40-45% aqueous solution of bovine albumin, does not affect platelet aggregation adversely. Platelet aggregation in eight patients with chronic idiopathic thrombocytopenic purpura was determined by this method. On the basis of the results the patients could clearly be divided into two groups: four patients with normal aggregation and four with a qualitative platelet defect. In contrast to the other patients, the group with an in vitro platelet functional defect all had more prolonged bleeding times and the presence of a serum antiplatelet antibody.
The most widely applied technique for investigating platelet function in vitro is the aggregation method introduced by Born (1962) . This method, however, requires a reasonably high concentration of platelets in the platelet rich plasma (PRP) and can thus not be applied as such for the investigation of patients with thrombocytopenia. We describe a method used by Walsh (1972) for studying platelet coagulation activities, which was modified and adapted to concentrate platelets in cases of thrombocytopenia. After assessment of the efficiency of the concentration technique and its influence on in vitro platelet aggregation it was applied in a study of platelet aggregation in patients with chronic immune type idiopathic thrombocytopenic purpura. (Heyns et al. 1974) Blood was obtained by clean venesection with disposable polystyrene syringes and siliconised needles from normal human volunteers or patients who had not taken aspirin or any other drugs known to affect platelet function for at least two weeks before the test. Ten parts of venous blood were added to one part 3 13% (w/v) trisodium citrate in polystyrene test tubes. The samples were centrifuged at room temperature for 15 minutes at 160 g (PRP) and platelet poor plasma (PPP) was prepared by centrifugation at 2500 g for 20 minutes. Test PRP Received for publication 30 May 1978 was prepared by adjusting the platelet count of PRP to that desired by dilution with a suitable volume of PPP. All experiments were completed within three hours of venesection, and results were accepted only if platelets aggregated with 5 tkmol/l ADP showed no functional deterioration at the end of the experiment. All glassware used was siliconised (Repelcote, Hopkin and Williams Ltd). Platelets were counted with a Coulter model FN particle counter (Bull et al., 1965) in normal controls, or in triplicate with phase contrast microscopy (Brecher and Cronkite, 1950) if platelets of thombocytopenic patients were used.
Material and methods

PREPARATION OF PRP
MEASUREMENT OF PLATELET AGGREGATION (Born, 1962; Born and Cross, 1963) Platelet aggregation was measured turbidimetrically at 370C in a Payton dual-channel aggregometer with continuous stirring (1000 rpm) of PRP. The integrated recorder was calibrated for full-scale deflection based on the optical density of PRP and PPP. Aggregating agents in 10 pl volumes were added to 0 5 ml PRP, and concentrations were expressed as final cuvette concentrations. The maximal change in optical density of PRP was related to the difference in optical density between PRP and PPP, and the result was expressed as percentage platelet aggregation.
REAGENTS
Adenosine diphosphate (ADP) and epinephrine were supplied by Sigma Chemical Co (St Louis, Mo, USA); collagen fibril suspension was supplied by Hormon-Chemie (Munich, West Germany). Bovine albumin was obtained in powdered crystallised form from BDH Chemicals, Poole, UK and a 40-45 % (w/v) aqueous solution was made by layering 50 g of albumin over the top of 100 ml distilled water, which was left to stand at 40C for 48 hours and then brought to pH 7 0 (Walsh, 1972) . Calcium-free Tyrode's solution was prepared according to Walsh (1972) .
Concentration ofPRP (modified from Walsh, 1972) PRP was prepared and 10 ml was carefully layered onto 1 ml 40% bovine albumin in a 10 ml roundbottomed polystyrene tube. The interface between the albumin and PRP was gently agitated with a stirring rod, and the stoppered tube was centrifuged at room temperature for 20 minutes at 2500 g. The platelets were sedimented into a band approximately 0 5 cm broad. The supernatant PPP was removed with a Pasteur pipette and 10 ml PRP was again added. The process was repeated, if necessary, until PRP-albumin of adequate platelet count was obtained.
Bleeding time was performed by the standardised template Ivy method (Mielke et al., 1969) .
Platelet antibody was assayed by a simplified immuno-injury platelet factor 3 release method (Hirschman and Gralnick, 1974) .
PATIENTS
Eight women with chronic immune type thrombocytopenia (ITP) were examined. None had undergone splenectomy at the time of examination.
Results
EFFECT OF PRP-PLATELET COUNT ON PLATELET AGGREGATION
Platelet aggregation studies with 0 5 ,tmol/l ADP, 5 ,umol/l ADP, and 3 mg/i collagen were performed on PRP prepared from six normal subjects. The PRP was diluted with PPP to platelet counts varying between 300 and 15 x 109/l. The results of six sets of serially diluted platelet specimens are given in Table 1 .
Since aggregation induced by the same aggregating agent varies in different individuals, platelet aggregation induced in 300 x 109/l-PRP was regarded as 100% and all other results were adjusted proportionately for comparison. Aggregation induced by ADP and collagen was reproducible and acceptable, considering the relative crudity of the test method, at platelet counts as low as 30 x 109/l.
A. du P. Heyns, J. Fraser, and F. P. Retief The effect of the concentration procedure on platelet aggregation was also assessed by another means. Aggregation response to ADP and collagen of normal subjects' PRP adjusted to a platelet count of 300 x 109/l was measured. The PRP was diluted to a platelet count of 30 x 109/l with the subject's own PPP and then concentrated to a PRP with a platelet count of 180 x 109/1. Retesting aggregation of this concentrated PRP with 5 gmol/l ADP and 3 mg/i collagen revealed comparable percentage aggregation in all three experiments (Table 3) . A secondary aggregation wave could not be demonstrated in platelets centrifuged into the albumin gradient ( Figure) .
PLATELET FUNCTIONS IN PATIENTS WITH ITP
The platelets of the eight patients with ITP were subjected to the concentration procedure for only Table 4 .
On the basis of in vitro platelet aggregation results the patients can clearly be divided into two groups: four patients with normal platelet aggregation and four with qualitative platelet defect. The group with an in vitro functional defect all had more prolonged standardised bleeding times compared with that of the normal platelet function patients. In none of the patients with normal platelet function could a serum platelet antibody be demonstrated whereas all four patients with thrombopathia had a platelet antibody.
Discussion
The in vitro study of platelet function in an aggregometer (Born, 1962 ) is a useful and simple method for assessing qualitative platelet defects if certain variables such as rate of stirring and temperature are carefully controlled (Weiss, 1972) . The method requires a reasonable concentration of platelets in the PRP, and since this is usually standardised at about 300 x 109/l, the method cannot readily be applied (Sanderson, 1973) or albumin (LevyToledano and Bodevin, 1973) . We have modified the albumin density gradient separation method of Walsh (1972) to concentrate platelets. The platelets of the PRP are sedimented into a density gradient between plasma and albumin. Physical injury to platelets is minimised since the gradient provides a cushion, which prevents disruption. Since we do not attempt to wash platelets free of plasma, problems affecting platelet function in the absence of a normal plasma milieu were not encountered (Walsh et al., 1977) . Platelets concentrated and rediluted with varying volumes of PPP or Tyrode's solution aggregated well with collagen and ADP ( Table 2 ). The secondary aggregation wave, however, consistently disappeared ( Figure) . The results depicted in Tables  2 and 3 and the Figure demonstrate that the concentration procedure used has no other adverse effect on platelet function as measured in the aggregometer. Although platelet aggregation cannot be determined reliably on PRP with low platelet counts (Hutton, 1966) , the advent of sensitive self-calibrating aggregating detectors with an integrated recorder, blowing full-scale deflection between optical density of PRP and PPP, makes this more feasible (Levine, 1976) . With our aggregometer and recorder, reproducible aggregation curves could be attained in PRP with platelet counts as low as 30 x 109/1 (Table 1) . This allowed assessment of platelet aggregation in thrombocytopenic patients after only one concentration cycle procedure. This further minimises damage to platelets by repeated centrifugation.
A qualitative defect of platelets in immune thrombocytopenic purpura has been documented by Clancy et al. (1972) and the association of antiplatelet antibody and functional platelet disorders confirmed (Regan et al., 1974; Zahavi and Marder, 1974 ). Clancy's 11 patients with chronic autoimmune thrombocytopenic purpura in remission, 10 of whom had had splenectomy, all had platelet counts greater than 140 x 109/l. All but two of these had impaired platelet aggregation, and the severity of the platelet defect correlated with the course of the disease. In 1974 Karpatkin's group described abnormal platelet function in 12 of 21 consecutive patients with systemic lupus erythematosus (Regan et al., 1974) , and Zahavi and Marder (1974) demonstrated an acquired storage pool disease in a patient with a connective tissue disorder and antiplatelet antibody. The easy bruising syndrome in women is also often associated with antiplatelet antibody and abnormal platelet function despite a normal platelet count (Lackner and Karpatkin, 1975) .
We report on eight women with chronic idiopathic thrombocytopenia. They all had low platelet counts (13-60 x 109/I) and none had had a splenectomy at the time of the investigation. Platelet aggregation studies were performed on concentrated PRP, and in all cases the minimum requirement for adequate assessment of aggregation, a PRP-platelet count of 30 x 109/l, was achieved with one concentration procedure cycle.
This study demonstrates abnormal platelet function in half the patients with chronic ITP not in remission. The results suggest that the severity of the functional platelet defect correlates with the bleeding time and that a demonstrable defect is associated with a positive serum antiplatelet antibody. It has been shown that the standardised template bleeding time is inversely related to the platelet count at levels of 100 x 109/1 and less (Harker and Slichter, 1972) . These investigators also showed a shortening of the predicted bleeding time in patients with ITP and suggested that these platelets have enhanced haemostatic capacity, confirming previous animal and in vitro studies (Hirsh et al., 1968; Karpatkin, 1969) . Our small series confirms this relationship between a short bleeding time and a low platelet count in ITP. The association between antiplatelet antibody and functional platelet disorders has been suggested by other reports (Clancy et al., 1972; Lackner and Karpatkin, 1975) . Clancy et al. (1972) found an inhibitor of platelet aggregation in the globulin fraction of serum from patients with ITP and platelet functional defects. The antiplatelet function factor could be specifically removed with antihuman IgG, suggesting that it was an IgG antibody. We measured antiplatelet antibody by the platelet factor 3 immuno-injury technique (Hirschman and Gralnick, 1974) , and in this group of patients it was positive in four of the eight patients. As is evident ( 
